Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

cascade_chemistry_new_facility_rendering_highres

Cascade Chemistry begins $14m manufacturing facility expansion

February 19, 2021 Medical Communications Cascade Chemistry, manufacturing

Cascade Chemistry, a leading pharmaceutical contract development and manufacturing organisation, has initiated the $14 million construction of new facilities to …
News
cream-4713579_1920

Dermavant announces positive Phase III findings for psoriasis treatment tapinarof

February 19, 2021 Medical Communications Dermavant Sciences, psoriasis

Dermavant Sciences has announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, a long-term, open-label …
News

RedHill enters manufacturing deal with Cosmo for two key products

February 19, 2021 Medical Communications RedHill Biopharma

RedHill Biopharma has announced agreements with Cosmo Pharmaceuticals to manufacture two of RedHill’s key products. Cosmo will manufacture Movantik, RedHill’s …
News
top_10_image_2_9

Pharmafile.com’s top 10 news stories of the week

February 12, 2021 Medical Communications

Over the past week, AstraZeneca’s COVID-19 jab has been at the centre of disputes about vaccine efficiency both in older …
News
opdivo_1_1

NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use

February 12, 2021 Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …
News
who_flag

AstraZeneca COVID-19 vaccine still restricted, despite WHO assurances

February 12, 2021 Medical Communications AstraZeneca, COVID-19

Several European countries have continued to impose age restrictions on their rollouts of the Oxford University-AstraZeneca vaccine, despite WHO’s repeated …
News
ipos0_l

FDA approves Regeneron’s Evkeeza for HoFH

February 12, 2021 Medical Communications FDA, Regeneron

The FDA has approved Regeneron’s Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat …
News

Arthritis drug tocilizumab cuts COVID-19 deaths in hospital trial

February 12, 2021 Medical Communications COVID-19

The rheumatoid arthritis drug tocilizumab can reduce the risk of death in severe COVID-19 patients and shorten the time spent …
News
elizabeth_crain

Exscientia appoints Moelis & Company COO Elizabeth Crain to Board of Directors

February 10, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

AI-driven pharma-tech company Exscientia has appointed Elizabeth Crain to their Board of Directors.
Appointment
top_10_image_2_9

Pharmafile.com’s top 10 news stories of the week

February 5, 2021 Medical Communications COVID-19

In the last week, a number of COVID-19 vaccine developments have been made. Johnson & Johnson’s one-shot jab was found …
News
astrazeneca-sign

New Oxford University-AstraZeneca vaccine against COVID-19 mutations could be available by October

February 5, 2021 Medical Communications AstraZeneca, COVID-19

Oxford University and AstraZeneca could release a new vaccine by October in order to counter the new mutations of COVID-19 …
News
pfizer_building_logo1

Pfizer withdraws application for emergency vaccine authorisation in India

February 5, 2021 Medical Communications COVID-19, Pfizer

Pfizer has withdrawn its application in India for emergency use authorisation of its vaccine, which it has produced with German …
News
candida_albicans_248_35

Hyloris and Purna Female Healthcare partner to develop novel women’s health product

February 5, 2021 Medical Communications Hyloris, women

Hyloris Pharmaceuticals and Purna Female Healthcare (PFH), a spin-off founded by Purna Pharmaceuticals and Creafund, have entered into a partnership …
News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi misses target in Phase III head and neck cancer trial

February 5, 2021 Medical Communications AstraZeneca, Cancer

AstraZeneca’s Imfinzi (durvalumab) has failed to improve overall survival (OS) for patients with recurrent or metastatic head and neck cancer …
News
mark_wilcox_002

Destiny Pharma appoints Professor Mark Wilcox to its Scientific Advisory Board

February 4, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening …
Appointment
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026